Shattuck Labs (STTK)

• Market cap: $54.9M
• 1 day: 10.58%
• 5 days: 0.00%
• 1 month: 3.60%
• 3 months: -69.25%
• 6 months: -72.42%
• Year to date: -84.79%
• 1 year: -82.17%
• 5 years: -94.06%
• 10 years: -94.06%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Employees: 75

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

7,500% more call options, than puts

Call options by funds: $304K | Put options by funds: $4K

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

6% more funds holding

Funds holding: 72 [Q2] → 76 (+4) [Q3]

3.7% more ownership

Funds ownership: 71.08% [Q2] → 74.78% (+3.7%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

6% less capital invested

Capital invested by funds: $130M [Q2] → $123M (-$7.79M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2 74% upside
• Avg. target: $2 74% upside
• High target: $2 74% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Citigroup Yigal Nochomovitz 28% 1-year accuracy 13 / 46 met price target

74% upside $2

Neutral Downgraded

2 Oct 2024